Catalyst Pharmaceuticals Stock Statistic Functions Linear Regression Angle

CPRX Stock

USD 23.23 -0.16 -0.68%

Use the statistic functions workspace to apply Linear Regression Angle function and other studies to Catalyst Pharmaceuticals. The focus on statistical functions describing dispersion and variability helps organize trend, volatility, and risk context for Catalyst Pharmaceuticals.Enter Time Period to start the analysis.

Symbol

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Linear Regression Angle indicator plots the angel of the trend line for each Catalyst Pharmaceuticals data point.

Catalyst Pharmaceuticals Technical Analysis Modules

Most technical analysis of Catalyst Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Catalyst from various momentum indicators to cycle indicators. When you analyze Catalyst charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

	Cycle Indicators
	Math Operators
	Math Transform
	Momentum Indicators
	Overlap Studies
	Pattern Recognition
	Price Transform
	Statistic Functions
	Volatility Indicators
	Volume Indicators

Stock Overview, Methodology & Data Sources

Catalyst Pharmaceuticals is scheduled to announce its earnings this week.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. As a large-cap equity, Catalyst Pharmaceuticals is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 23.62, P/B of 2.99, profit margin of 36.39%. Catalyst Pharmaceuticals has a market cap of 2.86 B, P/E of 23.62, ROE of 25.49%.

Methodology

Unless otherwise specified, financial data for Catalyst Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Catalyst (USA Stocks:CPRX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Catalyst Pharmaceuticals is covered by 7 analysts. 3 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, Raymond James, Bernstein Research, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Catalyst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Catalyst Pharmaceuticals' short interest history, or implied volatility extrapolated from Catalyst Pharmaceuticals options trading.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.

	Momentum Invested few shares	Go
	FinTech Invested over 20 shares	Go
	Macroaxis Index Invested over 60 shares	Go
	Social Domain Invested few shares	Go
	Software Invested few shares	Go
	Hedge Favorites Invested over 200 shares	Go
	Baby Boomer Prospects Invested over 20 shares	Go
	Macroaxis Picks Invested few shares	Go

More Resources for Catalyst Stock Analysis

Reviewing Catalyst Pharmaceuticals commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Catalyst Stock:

How To Invest In Catalyst

Details

Is Catalyst Stock a good investment?

Details

What is Catalyst Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Catalyst Pharmaceuticals has a market cap of 2.86 B, operating margin of 40.53%, ROE of 25.49%. See Trending Equities for portfolio-level analysis. This suggests a position in Catalyst Pharmaceuticals within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Our How to Buy Catalyst Stock guide explains the steps to invest in Catalyst Pharmaceuticals stock.

Analysis related to Catalyst Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Quarterly Earnings Growth

-0.06

Earnings Share

1.68

Revenue Per Share

4.816

Quarterly Revenue Growth

0.076

Return On Assets

0.1648

Investors evaluate Catalyst Pharmaceuticals using market value and book value, each describing different facets of the business. Catalyst Pharmaceuticals' market capitalization is 2.86 B. A P/B ratio of 2.99 indicates the market values Catalyst Pharmaceuticals above its accounting book value. Enterprise value stands at 2.15 B. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.

The concept of value for Catalyst Pharmaceuticals differs from its quoted price, since each reflects a different lens. For Catalyst Pharmaceuticals, key inputs include a P/E ratio of 23.62, a P/B ratio of 2.99, a profit margin of 36.39%, and ROE of 25.49%. Trading price represents the transaction level agreed by market participants.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Catalyst Pharmaceuticals Stock Statistic Functions Linear Regression Angle

Catalyst Pharmaceuticals Technical Analysis Modules

Stock Overview, Methodology & Data Sources

Methodology

Analyst Sources

This content is curated and reviewed by:

Trending Themes

More Resources for Catalyst Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY